RECURRENT MALIGNANT SOLID NEOPLASM

This study tests whether combining three drugs (axatilimab, retifanlimab, and paclitaxel) is safe and works against advanced or metastatic solid tumors. About 38 adults with tumors that have spread or come back will receive the combination. The goal is to find the best dose and s…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…

This study tests a new drug combination (DT2216 plus irinotecan) in children, teens, and young adults whose solid tumors have returned or not responded to treatment. The goal is to find the safest dose and see if the combination can shrink tumors. The study includes a special gro…

This study compares the drug neratinib alone versus neratinib plus palbociclib in people with HER2-positive gynecologic and other solid tumors (excluding breast cancer). Both drugs block signals that make cancer cells grow. The goal is to see if the combination shrinks tumors or …

This early-phase trial tests a drug called talazoparib (a PARP inhibitor) combined with one of three other drugs (palbociclib, axitinib, or crizotinib) in people with advanced or metastatic solid tumors. The goal is to find the safest dose and see if the combinations can help con…

This early-phase study tests the safety and best dose of TAK-243, a drug that blocks a key enzyme cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma who have tried other treatments will receive TAK-243. The goal is to find side effects and the right…

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or never fully went away. It tests two different drug combinations that damage cancer cell DNA to kill the tumor. The goal is to find the safest dose and see if the tumors shrink or disap…

This study tests a drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking signals that he…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a parenting support program for 120 parents with advanced cancer and their spouses. The program aims to reduce parenting worries, improve family communication about cancer, and boost emotional well-being. Participants must have a child aged 4–16 living at home.

This study follows 2,000 people who have had ovarian or other solid cancers to understand why some later develop blood cancers. Researchers will look at genetic changes and treatment history to identify risk factors. The goal is to improve monitoring and prevention for cancer sur…

This study collects tissue and blood samples from up to 5,000 cancer patients. The samples are used to create lab models, like cell lines and tumor grafts, to help scientists study cancer and test new drugs. It does not offer direct treatment but supports future research.

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…